Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL93390 | 0.93 | — | — | |
| Hydroxyamine SCHEMBL12488720 | 0.90 | FFAR3 (0.30) | FFAR3 | |
| SCHEMBL6492 | 0.80 | TSHR (0.39) | TSHRNFKB1CYP2C19 | |
| SCHEMBL6567522 | 0.80 | TSHR (0.34) | TSHRNFKB1CYP2C19 | |
| Hypochlorous Acid SCHEMBL15633664 | 0.79 | TSHR (0.40) | TSHRNFKB1CYP2C19 | |
| Methacrylic Acid SCHEMBL2835381 | 0.77 | FFAR3 (0.33) | FFAR3TSHRNFKB1CYP2C19 | |
| SCHEMBL1082541 | 0.77 | TSHR (0.43) | TSHRNFKB1CYP2C19 | |
| SCHEMBL2363259 | 0.77 | TSHR (0.43) | TSHRNFKB1CYP2C19 | |
| Hno SCHEMBL15954661 | 0.75 | TSHR (0.37) | TSHRNFKB1CYP2C19 | |
| Phosphoric Acid SCHEMBL6824270 | 0.75 | TSHR (0.38) | TSHRNFKB1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2620429-A1 | Hydroxylamine compounds and methods of their use | Colby Pharmaceutical Company (US) | 2013-07-31 | — | — | EP | disclosed |
| US-20080280890-A1 | HYDROXYLAMINE COMPOUNDS AND METHODS OF THEIR USE | COLBY PHARMACEUTICAL COMPANY | 2008-11-13 | — | — | US | disclosed |
| US-20080200405-A1 | Drug Resistance Reversal In Neoplastic Disease | COLBY PHARMACEUTICAL COMPANY | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280890-A1 | HYDROXYLAMINE COMPOUNDS AND METHODS OF THEIR USE | HDGF, HMOX1, HMOX2 | FFAR3 1030/4885TSHR 1831/4885NFKB1 966/4885 |
| US-20080200405-A1 | Drug Resistance Reversal In Neoplastic Disease | VHL, ABCC1, SLC11A2 | FFAR3 2920/4885TSHR 2111/4885NFKB1 1270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.